OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPa Blockade in Two Ongoing Trials at ASCO 2025
Events
You confirm that you have read our privacy policy. You can unsubscribe at any time by using the unsubscribe links.